Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 1;537(7618):50-6.
doi: 10.1038/nature19323.

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny  1 , Ping Chiao  1 , Thierry Bussière  1 , Paul H Weinreb  1 , Leslie Williams  1 , Marcel Maier  2 , Robert Dunstan  1 , Stephen Salloway  3 , Tianle Chen  1 , Yan Ling  1 , John O'Gorman  1 , Fang Qian  1 , Mahin Arastu  1 , Mingwei Li  1 , Sowmya Chollate  1 , Melanie S Brennan  1 , Omar Quintero-Monzon  1 , Robert H Scannevin  1 , H Moore Arnold  1 , Thomas Engber  1 , Kenneth Rhodes  1 , James Ferrero  1 , Yaming Hang  1 , Alvydas Mikulskis  1 , Jan Grimm  2 , Christoph Hock  2   4 , Roger M Nitsch  2   4 , Alfred Sandrock  1
Affiliations

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny et al. Nature. .

Update in

  • Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.
    Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Sevigny J, et al. Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809. Nature. 2017. PMID: 28640269

Abstract

Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.

Trial registration: ClinicalTrials.gov NCT01677572.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Nucl Med. 2013 Jan;54(1):70-7 - PubMed
    1. J Immunol. 1989 Oct 15;143(8):2595-601 - PubMed
    1. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):4012-7 - PubMed
    1. Lancet Neurol. 2013 Apr;12(4):357-67 - PubMed
    1. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1550-5 - PubMed

MeSH terms

Associated data